{"prompt": "[\"Appendix 1: Schedule of Activities (cont'd)\", 'End of', 'Treatment Continuation', 'Follow-up', 'Screening', 'Baseline', 'Treatment Cross-over Period', 'Treatment', 'Period [a]', 'Period [c]', 'Visit [b]', '15', '11', 'Study Cycle', '1', '2', '3', '4', '5', '6', '7', '(or last', '[d]', 'treatment', 'cycle) [e]', ' 28 days', 'Day', '-28 to -1', '-7 to -1', '1', '1', '1', '1', '1', '1', '1', '1', '1', 'from last', 'study dose', 'P+H IV or pertuzumab', 'every cycle from C7 until', 'the end of EBC treatment', 'and trastuzumab FDC SC', '[w]', 'ALT = alanine aminotransferase; ANC = absolute neutrophil count; ACS/ASCO: American Cancer Society / American Society of', 'Clinical', 'Oncology;', 'AST = aspartate aminotransferase; EBC= early breast cancer ; ECHO = echocardiogram; ECOG = Eastern Cooperative Oncology Group; EORTC QLQ-C30', '= European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; FDC SC = fixed-dose combination for subcutaneous', 'administration; FU = follow-up; HCPQ = Healthcare Professional Questionnaire; LDH = lactate dehydrogenase; LVEF = left ventricular ejection', 'fraction;', 'MUGA = multi-gated acquisition; PPQ = Patient Preference Questionnaire; P+H IV = Perjeta intravenous + Herceptin intravenous; TASQ-IV/SC = Therapy', 'Administration Satisfaction Questionnaire for Intravenous Administration / Subcutaneous Administration; WBC = white blood', 'cell.', 'Notes Unless otherwise specified, assessments should be performed within three days of the scheduled visit. On treatment days, all assessments should be', 'performed prior to dosing, unless otherwise specified. For all protocol-mandated study visits, a time window of + 3 days is allowed. If a protocol mandated study', 'visit coincides with a holiday and/or weekend that preclude the visit, the visit should be scheduled on the nearest following feasible date.', 'a.', 'Either pertuzumab and trastuzumab FDC SC or P+H IV will be selected by the patient for study treatment during the Treatment Continuation Period.', 'During', 'this period, pertuzumab and trastuzumab FDC SC or P+H IV will be administered for the number of 3-weekly cycles calculated based on the', 'number of Perjeta and Herceptin cycles received as neoadjuvant treatment prior to study entry and P+H IV and pertuzumab and trastuzumab FDC SC', 'cycles (six total cycles) received during the Treatment Cross-over Period. A total of 18 cycles of anti-HER2 treatment should be administered for EBC', 'treatment unless disease recurrence, unacceptable toxicity or patient withdrawal from treatment necessitates early cessation of treatment. No specific', 'investigations are required per protocol for Cycles 8-10 and Cycles 12-14 during the Treatment Continuation Period, although the PI', 'may', 'perform', 'safety', 'laboratory', 'assessments or other tests per institutional practice (these results are not required to be reported in the eCRF). However, information on treatment administration will', 'be collected, and new or worsened clinically significant abnormalities should be recorded as AEs on the Adverse Event eCRF.', 'b. End of Treatment Visit to be performed within 28 days ( 7 days) of the administration of the last dose of any study drug.', 'C. Study patients will be followed for at least three years from randomization. A follow-up visit should occur at least every six months during this period.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '98 / Protocol MO40628, Version 12'][\"Appendix 1: Schedule of Activities (cont'd)\", 'd. If study treatment Cycle 12 is planned as last study treatment cycle (i.e. corresponding to Cycle 18 of neo/adjuvant anti-HER2 treatment), all planned', 'assessments may be delayed to study treatment Cycle 12', 'e. The number of the last treatment cycle in Treatment Continuation Period will depend on number of neoadjuvant cycles with Perjeta', 'and', 'Herceptin.', 'A', 'total', 'of 18 cycles of HER2-targeted therapy should be administered over neo/adjuvant treatment (i.e. neoadjuvant cycles + Treatment Cross-over Period', 'Cycles + Treatment Continuation Period cycles = 18 neo/adjuvant cycles).', 'f.', 'Results of standard-of-care tests or examinations performed prior to obtaining informed consent but within 28 or 7 days of randomization (as indicated)', 'may be used; such tests do not need to be repeated for screening.', 'g. Pathology reports from initial breast cancer diagnosis and from breast cancer surgery will be collected. Results of local HER2 and hormone receptor', 'testing conducted prior to neoadjuvant therapy will also be collected.', 'h. Must be performed pre-dose on study treatment dosing days', 'i. Complete physical examinations should include physical measurements (body weight in kilograms and height in centimetres) and evaluation of the head,', 'eyes, ears, nose and throat, and the cardiovascular, dermatologic, musculoskeletal, respiratory, gastrointestinal, genitourinary, and neurologic', 'systems.', 'Any abnormality identified at baseline should be recorded on the General Medical History and Baseline Conditions eCRF. Limited physical examinations', 'are symptom-directed and, in addition to the scheduled examinations indicated, may be conducted as clinically indicated. New or worsened clinically', 'significant abnormalities observed post-baseline should be recorded as AEs on the Adverse Event eCRF. During the Follow-up Period, physical', 'examinations should be conducted in accordance with institutional practice or the American Cancer Society/American Society of Clinical Oncology Breast', 'Cancer (ACS/ASCO) Breast Cancer Survivorship Care Guideline [Runowicz et al. 2016, see Appendix 4].', 'j.', 'Vital signs (heart rate, blood pressure, temperature, respiration rate) will be taken before and after study treatment administration. Heart rate, blood', 'pressure, and respiration rate should be obtained while the patient is seated.', 'k. Weight will be measured during screening and on Day 1 of each cycle prior to treatment administration. If variation of + 10% compared with baseline', 'occurs, Herceptin IV dosing should be recalculated. Weight at the time the Herceptin IV dose is recalculated will be considered as baseline for', 'subsequent evaluations of degree of weight change with respect to Herceptin IV dose modification requirements.', 'I.', 'Clinical breast examination should be performed to detect signs of residual disease / local recurrence prior to study entry and to detect locoregional', 'relapse during the Treatment Cross-over and Treatment Continuation Periods, and at the End of Treatment Visit. During the Follow-up Period, clinical', 'breast', 'exams should be conducted in accordance with institutional practice or the ACS/ASCO Breast Cancer Survivorship Care Guideline [Runowicz et', 'al. 2016, see Appendix 4].', 'm. LVEF may be assessed by ECHO or MUGA however the same method should be used throughout the study for each patient and should be performed', 'and assessed by the same assessor where possible. During the study treatment periods, results of LVEF assessments must be reviewed prior to study', 'treatment administration on the scheduled visit day. During the Follow-up Period, LVEF should be assessed at 6, 12, and 24 months after last study', 'treatment or per institutional practice.', 'n.', 'Haematology: haemoglobin, total WBC, ANC / neutrophils, platelet count. Limited biochemistry: alkaline phosphatase; AST; ALT; LDH; total bilirubin;', 'creatinine. Albumin should be measured at Screening for determining patient eligibility. Bilirubin fractions (direct and indirect) must be included if total bilirubin', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '99 / Protocol MO40628, Version 12']\n\n###\n\n", "completion": "END"}